Dr. Irwin Goldstein, president of the Institute for Sexual Medicine, extolled the approval of Addyi, the first-ever drug approved to treat women's sexual dysfunction. He says it'll open the door for further conversation and research about women's health.
Pending FDA approval, women could soon have their own drug designed to increase sexual desire.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Using a compound that Boehringer Ingelheim abandoned two years ago, Sprout Pharmaceuticals is taking a $20 million step toward developing a drug therapy specifically for hypoactive sexual desire disorder (HSDD) in women. The Raleigh, North Carolina-based drug company has raised $17.6 million of a $20 million round of financing, according to a recent U.S. Securities […]
Could a female Viagra be developed? Sprout Pharmaceuticals wants to find out if it can make a so-called pink Viagra and it’s picking up where German pharmaceutical company Boehringer Ingelheim left off. Sprout acquired flibanserin, a compound that Boehringer pursued as a drug to treat hypoactive sexual desire disorder, or HSDD — essentially, diminished sexual […]